HER2status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhancedin situhybridization (SISH)

Abstract

HER2 gene amplification was found in 41% of Vietnamese breast cancers; this level is considerably higher than that previously found in a series of Swedish breast cancer women. The HER2-positive tumors were more often found in post-menopausal women than in ER negative tumors.

Immunohistochemical Profile of Infiltrating Ductal Carcinoma Breast (Not Otherwise Specified) - A Study Of 100 Cases

“…In the present study, there was seen significant correlation between age of the patient and ER (p value=0.000), PR (p value=0.000) and HER2/neu (p value=0.000) expression in present study. Studies by Desai SB et al, [28] Dodiya H et al, [29] Thang VH et al, [30] and Ganesan M et al, [31] showed similar results. The majority of receptors positive cases were postmenopausal in our study.…”

Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc-SISH) and Comparison with Fluorescence ISH (FISH)

“…HER2/neu oncogene codes the trans-membrane protein that has tyrosine kinase activity (Thang et al, 2011). HER2/Neu (cerbB2), a member of the epidermal growth factor receptor family, which plays an important role in breast cancer pathogenesis, is localized in the long arm of the 17 th chromosome (17q11.2-q12).…”

“…The response to herceptin treatment is directly related to the HER2 status of the patient (Dietel et al, 2007;Thang et al, 2011). Therefore, it is imperative to identify the method that defines the HER2 status with the greatest safety; this issue remains controversial.…”

“…Amplification of the HER2/neu gene in 18-20% of patients with breast cancer produces the primary mechanism of HER2 protein overexpression (PenaultLlorca et al, 2009;Thang et al, 2011;Dekker et al, 2012). The HER2 gene is a tumor marker associated with rapid tumor growth, increased recurrence rate after surgery, and decreased life expectancy (Penault-Llorca et al, 2009;Thang et al, 2011).…”

“…The HER2 gene is a tumor marker associated with rapid tumor growth, increased recurrence rate after surgery, and decreased life expectancy (Penault-Llorca et al, 2009;Thang et al, 2011). HER2 positivity has a powerful predictive value related to a good response to anthracycline-based chemotherapy and a poor response to hormonal therapy (Slamon et al, 1987;Paik and Park, 2001).…”